A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial-Reference-Cited by-同舟云学术

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Published:2014-07 Issue:7 Volume:2 Page:527-538
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Boyle Michael P,Bell Scott C,Konstan Michael W,McColley Susanna A,Rowe Steven M,Rietschel Ernst,Huang Xiaohong,Waltz David,Patel Naimish R,Rodman David

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference21 articles.

1. Cystic Fibrosis Foundation Patient Registry: 2012. Annual Data Report to the Center Directors. Bethesda, Maryland; 2013.

2. Cystic fibrosis;Rowe;N Engl J Med,2005

3. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease;Matsui;Cell,1998

4. Targeting CFTR: How to treat cystic fibrosis by CFTR-repairing therapies;Amaral;Curr Drug Targets,2011

5. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation;Ramsey;N Engl J Med,2011

Cited by 380 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A rapid LC-MS/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma;Journal of Pharmaceutical and Biomedical Analysis;2024-09

2. Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial;The Lancet Respiratory Medicine;2024-08

3. Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFB): a clinical study protocol;2024-07-21

4. The Folding Pathway of ABC Transporter CFTR: Effective and Robust;Journal of Molecular Biology;2024-07

5. The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis;Journal of Cystic Fibrosis;2024-07